Clinical Trials Browser

Phase 1 × Plasmablastic Lymphoma × 1 year × Clear all

Plasmablastic Lymphoma

NCT05389423 2026-02-19

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Epstein-Barr Virus Infections

NCT05544019 2026-02-13

Study of SGR-1505 in Mature B-Cell Neoplasms

Phase 1 Recruiting

98 enrolled

LymphoidOther hematologic neoplasm

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Pyloric Stenosis, Hypertrophic, Lymphoma, Primary Effusion

NCT07113496 2025-08-13

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Phase 1 Not yet recruiting

27 enrolled

LymphoidPlasma cell

Plasmablastic Lymphoma, Burkitt Lymphoma, Multiple Myeloma, Recurrence

Clinical Trials

Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

Study of SGR-1505 in Mature B-Cell Neoplasms

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies